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Introduction
Internal tandem duplications (ITDs) of the FLT3 gene are present in 30-40% of acute promyelocytic leukemia (APL) patients. [1] [2] [3] [4] FLT3/ITDs are associated with poor outcome in most published studies in acute myeloid leukemia (AML). [1] [2] [3] 5 However, this correlation has not been found in APL where ITDs have only been associated with some adverse diagnostic clinical features (high WBC count, M3 variant morphology or bcr3 isoform), but not poor survival. 4, [6] [7] [8] [9] Previous studies analyzing the clinical utility of ITDs quantitative determination have suggested that only patients with high FLT3 mutant levels have a real inferior prognosis, but the majority of these reports only included AML with normal karyotype, 10, 11 or excluded APL patients. 5 Moreover, studies analyzing the impact of ITD length on outcome have yielded contradictory results, since the shorter survival attributed to patients with long ITDs 12 have not been confirmed by all authors. 5, 13 A number of pre-treatment characteristics have been described as prognostic factors in APL patients (reviewed by Mistry et al.) . 14 Among them, presenting leukocyte counts have the highest impact on outcome. [15] [16] [17] [18] In the same line, the level of PML-RAR! transcripts before treatment could have some predictive value. However, clinical studies with quantitative assessment of PML-RAR! transcripts at diagnosis are scanty and have produced conflicting results. 19, 20 These discrepancies may reflect technical variations or the lack of correction according to the blast cell percentage. 21 As far as other AML fusion transcripts are concerned, there are also conflicting results. For instance, some groups have observed a correlation between high levels of the AML1-ETO transcript at diagnosis and shorter survival, 20, 22 while some others have failed to find it. 23, 24 Our aim in the present study was to assess the prognostic relevance of FLT3-ITD quantification and sizing in addition to other factors such as PML-RAR! expression and clinical characteristics in a series of uniformly treated APL patients at diagnosis.
Design and Methods

Patients
Pre-treatment bone marrow (BM, n=124) or peripheral blood (PB, n=17) samples received at our reference laboratory of the University Hospital of Salamanca (Spain) were obtained from 141 adult APL patients who were entered into either the Spanish LPA96 25 (n=46) or LPA99 26 (n=95)
PETHEMA trials. Both protocols included an induction phase with ATRA plus idarubicin and three consolidation courses with idarubicin, mitoxantrone and idarubicin, followed by a maintenance phase with ATRA, methotrexate and mercaptopurine for 2 years. 25 In the LPA99 protocol the consolidation phase was modified by including ATRA plus higher doses of idarubicin for patients who were considered as being at intermediate-and high-risk of relapse. 26 In addition to using standard criteria, 26 as well as immunophenotyping 27 , all patients were confirmed by both RT-PCR and RQ-PCR analysis for PML/RAR! rearrangements.
RNA isolation and cDNA synthesis
Total RNA was isolated from BM and PB samples using the guanidinium tyocyanate/phenol chloroform method. Reverse transcription was performed on 1µg of total RNA according to the rules and protocols approved in the "Europe Against Cancer" (EAC) Program.
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Determination of FLT3 mutation status FLT3-ITD was examined by RT-PCR amplification of the juxtamembrane domain as previously described. 4 To obtain the size and the relative level of mutations, RT-PCR was performed using a fluorescently labeled primer with 6-FAM. Products were analyzed by Genescan analysis on a 3130
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The relative mutant level was calculated using the area under the peak and expressed as the ratio of mutant and wt FLT3 alleles. 3 To detect FLT3-D835 point mutations, the restriction fragment length polymorphism-mediated (RFLP) PCR assay was used by amplifying the exon 20 of the FLT3 tyrosine kinase domain. 4 In all cases, the presence of a D835 mutation was confirmed by sequencing of the amplified products with the BigDye
Terminator cycle sequencing chemistry (Applied Biosystems, Foster City, CA, USA). 
Quantification of PML-RAR! transcripts by real-time quantitative PCR
Results
Relationship between FLT3 status, PML-RAR! expression and pretreatment characteristics
FLT3 mutations were determined in 129 of the original cohort of 141 patients because some samples had been used up in previous studies. 4, 28, 33 In total, 39 (30%) of 129 patients had mutations: expressed the V-form (bcr2) and 51 (36%) expressed the S-form (bcr3). Because of the relative rarity of the bcr2 isoform, results for patients with bcr1 and bcr2 were joined for further analyses, as in other studies. [15] [16] [17] [18] After correction for blast cell percentage, there were not differences in the distribution of To better establish the risk of relapse at diagnosis, patients were stratified according to the Spanish score 18 /L) ( Table 1 ). There was a correlation between these categories and the subgroups of PML-RAR! expression, since the major proportion of patients at high risk of relapse belonged to the low-expression group (54% vs. 20% p=0.001).
As far as the immunophenotypic characteristics of leukemic cells were concerned, we only focused on CD34 and CD15 markers according to our previous results. 27 The group with low NCN had more CD34+ (30% vs. 11%, p=0.040) and CD15-cases (80% vs. 60%, p=0.099). These findings were translated into a higher frequency for immature phenotypes (CD34+/CD15-) in the group with less than 2700 NCN of the PML-RAR! transcript (30% vs. 10%, p=0.025).
Response to treatment, Relapse Free Survival and Overall Survival
A total of 141 patients were treated and evaluated for response. Of these, 122 (86.5%) achieved complete remission (CR). The remaining 19 patients (13.5%) died during induction treatment due to hemorrhage (n=9), therapy-related infection (n=9) or ATRA syndrome (n=1) at a median of 14 days after diagnosis (range 1-29 days).
Survival analysis of patients with FLT3 mutations revealed that although small differences existed between ITD-positive and negative cases (p=0.071) in terms of OS, patients with ITD mutations had a shorter RFS (68% vs. 90%, p=0.033). In the same way, increasing FLT3-ITD ratio (>0.66) was related with shorter 5-year RFS, with estimated probabilities of 90% for patients without
ITDs and 79% and 57% for patients with low and high ratios, respectively (p=0.048) ( Figure 1A ). With respect to the length of ITDs, increasing size (>60 nt.) was associated with a short 5-year RFS, with estimated probabilities of 90% for patients without ITDs and 100% and 27% for patients with small and large ITDs, respectively (p<0.0001) ( Figure 1B ). By contrast, the CR rate, RFS and OS probabilities were similar between patients with or without D835 mutations.
Concerning the two subgroups of PML-RAR! expression, the CR rate did not vary among them (81% vs. 89%, p=0.259) ( Table 1) . However, a worse outcome was observed in the low-expression group since they showed a highly significant shorter 5-year RFS (60% vs. 92%, p<0.0001) ( Figure   1C ). Since all deaths during the induction therapy in the present series were due to hemorrhagic complications, early infections, and ATRA syndrome, which are competing risks in evaluating leukemia-related mortality, we performed a landmark analysis beyond day 30 (median day for achieving the hematological response). In this analysis, we could confirm that patients with a low PML-RAR! expression really had a shorter 5-year OS compared to patients with high expression (70% vs. 88%, p=0.002) ( Figure 1D ). 
Prognostic factors: multivariate analyses
Impact of FLT3-ITD size and PML-RAR! levels on the risk stratification of APL
Since FLT3-ITD size and PML-RAR! levels were independent prognostic markers in addition to WBC count, we investigated the prognostic influence of these molecular parameters in patients with WBC !10 x 10 9 /L (n=87) and with WBC >10 x 10 9 /L (n=24). Patients with low counts showed a decreased incidence of ITD mutations (5%) with small sizes and elevated PML-RAR! fusion gene levels (median NCN: 4970). By contrast, patients with a high WBC count presented more ITDs (63%) with longer sizes (p<0.0001) and reduced transcript levels (median NCN: 2650, p<0.0001).
Accordingly, among these later patients the existence of an ITD longer than 60 nt. was able to identify a subgroup of patients with a very high risk of relapse: 23% vs. 79% probabilities of 5-year RFS (p<0.0001, Figure 2 ).
Discussion
In this series of acute promyelocytic leukemia (APL) patients we have evaluated the clinical impact of FLT3-ITD mutant level and size in combination with PML-RAR! expression before treatment. Our study demonstrated that both longer ITDs and lower PML-RAR! level at diagnosis characterize a small subgroup of patients with an extremely worse prognosis.
FLT3-ITDs have been associated with a worse prognosis in non-APL AML in most published
studies. [1] [2] [3] 5 However, the impact of these mutations on clinical outcome of APL patients seems to be marginal, since several reports did not find any relationship between ITDs and relapse risk or survival. 6, 7, 34, 35 However, these studies only analyzed the presence or absence of FLT3-ITD mutations but they did not examine either the mutant/wild type ratio or mutant size, what have been recognized recently as the real prognostic factors in non-APL AML. 3, 5, 10, 12 In a previous study from our group, 4 no significant differences in OS and disease-free survival were observed between FLT3 mutated and non mutated APL cases, despite ITDs correlated with adverse clinical features. In the present work, using a quantitative method in a larger number of patients, we have found a significant association of high FLT3-ITD ratios and sizes with a worse prognosis. It has been suggested that an increasing length of the inserted sequence induce constitutive activation of the kinase domain of the FLT3 receptor leading to increased proliferation and survival of myeloid precursor cells. 36 However, studies analyzing the impact on disease outcome of ITD size have produced conflicting results, partially explained by different screening techniques. 5, 12, 13 Our study is in accordance with the analysis of Stirewalt et al., 12 where increasing ITD size is associated with short OS and RFS in non-APL AML. Indeed, multivariate analysis for RFS confirmed that a long FLT3-ITD size is the most significant predictor of poor outcome, followed by low PML-RAR! levels and high WBC count.
Therefore, we investigated if both molecular parameters combined with WBC count could improve other risk classifications. 17, 18 Interestingly, within the high-risk group (WBC>10x10 9 / L) we could identify a small subgroup of patients at a very high risk of relapse (23% at 5 years) who were characterized by long ITDs and low expression of PML-RAR!.
The prognostic impact of PML-RAR! levels at the time of diagnosis of APL patients has been analyzed by few groups showing conflicting data. 19, 20 Gallagher et al. 19 did not find any association between pretreatment transcript levels and clinical outcome. By contrast, Schnittger et al. 20 observed a favorable prognosis for patients with low fusion gene expression. Our results do not favor any of these two studies, since low PML-RAR! levels were associated with poor prognosis in terms of short OS and RFS. The poor outcome of low PML-RAR! levels was in line with the presence of adverse clinical features, such high WBC count, high blast cell percentages in BM and PB and elevated LDH serum levels. A clear explanation for these results was not found. However, experimental data suggest that t(15;17) cells with low levels of transcripts are more efficient to develop APL in knock-in mice than those with high levels. 37 This could indicate that the acquisition of progression mutations leading to the development of APL would depend on an "optimal pathogenic PML-RAR! dose". 37 Moreover, in our series, those patients with a more immature and aggressive immunophenotype (CD34+/CD15-), 27, 38 showed low PML-RAR! levels, suggesting that immature blast cells probably have a lower ability to produce transcripts and higher capacity to develop resistance to the therapy.
However, the significance of this finding is at present unclear and needs further investigation. One potential experiment might be analyzing P M L -R A R ! levels before treatment in separated subpopulations, in order to compare the fusion gene expression of mature and immature phenotypes.
In summary, the present study shows that the length of ITD mutations and PML-RAR! transcript levels could be used as genetic markers for prognosis in APL allowing a more accurate patient risk classification. Nevertheless, these new prognostic parameters need to be validated in an independent series of patients before they could be implemented into the clinical practice. (32) 83 (80) 21 (20) 0.131
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22 (60) 15 (40) 68 (65) 36 (35) 0.519 (35 and 94 in the low-and high-expression groups, respectively). In the same way, immunophenotypic results were feasible for 106 patients (25 and 81 in the low-and high-expression groups, respectively), and the percentages were adjusted accordingly. ** Relapse-risk stratification according to Sanz et al. 
